Is X4 Pharmaceuticals Inc (NASDAQ: XFOR) a Risk-Worthy Bet for Bold Investors?

In the last trading session, 1.04 million X4 Pharmaceuticals Inc (NASDAQ:XFOR) shares changed hands as the company’s beta touched 0.42. With the company’s per share price at $0.95 changed hands at $0.09 or 10.04% during last session, the market valuation stood at $159.11M. XFOR’s last price was a discount, traded about -171.58% off its 52-week high of $2.58. The share price had its 52-week low at $0.57, which suggests the last value was 40.0% up since then. When we look at X4 Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.27 million shares, with the 3-month average coming to 0.49.

X4 Pharmaceuticals Inc (NASDAQ:XFOR) trade information

Instantly XFOR was in green as seen at the end of in last trading. With action 14.70%, the performance over the past five days has been green. The jump to weekly highs of 0.9600 added 10.04% to the stock’s daily price. The company’s shares are showing year-to-date upside of 13.43%, with the 5-day performance at 14.70% in the green. However, in the 30-day time frame, X4 Pharmaceuticals Inc (NASDAQ:XFOR) is 11.89% up. Looking at the short shares, we see there were 12.8 million shares sold at short interest cover period of 10.7 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

X4 Pharmaceuticals Inc (XFOR) estimates and forecasts

Data shows that the X4 Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -9.42% over the past 6 months, a 58.55% in annual growth rate that is considerably higher than the industry average of 15.50%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for X4 Pharmaceuticals Inc will rise 48.30%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 69.68%. The 2024 estimates are for X4 Pharmaceuticals Inc earnings to increase by 59.87%.

X4 Pharmaceuticals Inc (NASDAQ:XFOR)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.94% of X4 Pharmaceuticals Inc shares while 68.37% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 69.02%. There are 68.37% institutions holding the X4 Pharmaceuticals Inc stock share, with Bain Capital Life Sciences Investors, LLC the top institutional holder. As of Jun 29, 2023, the company held 9.71% of the shares, roughly 15.96 million XFOR shares worth $30.96 million.

NEA Management Company, LLC holds the second largest percentage of outstanding shares, with 9.11% or 14.99 million shares worth $29.07 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 5.28 million shares estimated at $10.25 million under it, the former controlled 3.21% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.69% of the shares, roughly 2.79 million shares worth around $3.57 million.

On Key

Related Posts